Calculated
DCF
Free cash flow, growth, discount rate, and terminal growth form an intrinsic value range.
43.48美元40.64美元50.96美元
+652%
40.64美元Current price is 651.8% above the base model value.
AL
HealthcareBiotechnologyUnited States
ALNY.US · Alnylam Pharmaceuticals, Inc.
NMS · US · USD
Latest price305.54美元
30D-2.51%
Vs. base value+652%
Research summary
ALNY.US latest organized financial period shows revenue year-over-year comparison is not complete and net income up 55.16% year over year. Current price is about 305.54美元, while the model base case is about 40.64美元; the price is 652% from the base case. This summary is intended for public-information research and model review.
Key financial trend
Unit: 美元
Revenue-
Net income3.14亿美元
Free cash flow4.65亿美元
Operating cash flow5.24亿美元
Price trend
Price date: 2026/04/23 · Updated: 2026/04/25 07:54
Valuation model range
Hover each model row to inspect formulas and inputs.
Current price305.54美元
Base value40.64美元
Vs. base+652%
Price date2026/04/23
43.48美元40.64美元50.96美元
+652%
Calculated
Owner Earnings
Uses recent net income as an owner-earnings proxy and discounts scenario growth.
47.12美元76.22美元99.32美元
+301%
76.22美元Current price is 300.8% above the base model value.
Calculated
Reverse DCF
Solves the forward FCF growth rate implied by the current price.
---
-
24.7%当前价格隐含未来 FCF 年化增长约 24.7%。
Calculated
Earnings Power Value
Estimates earnings power value without assuming growth.
32.70美元32.70美元32.70美元
+834%
32.70美元Current price is 834.5% above the base model value.
Updated: 2026/04/25 07:54
Ad placement
Quarterly and annual financial table
Financial DetailsShowing latest 5 / 80
| Period | Type | Revenue | Net Income | Free Cash Flow | Diluted EPS |
|---|---|---|---|---|---|
| 2025/12/30 | Annual | - | 3.14亿美元 | 4.65亿美元 | 2.33 |
| 2025/09/29 | Annual | - | 2.02亿美元 | - | 1.51 |
| 2025/06/29 | Annual | - | -9,048万美元 | - | -0.7 |
| 2024/12/30 | Annual | - | -2.78亿美元 | -4,259万美元 | -2.18 |
| 2023/12/30 | Annual | - | -4.4亿美元 | 4,195万美元 | -3.52 |
Related stocks
View allAd placement